Palliative Endoscopic Esophageal Stenting for Malignant Esophageal Tumour Complications: A Clinical Case and Single Centre Experience in Latvia-Reference-Cited by-同舟云学术

Palliative Endoscopic Esophageal Stenting for Malignant Esophageal Tumour Complications: A Clinical Case and Single Centre Experience in Latvia

Published:2020-04-01 Issue:2 Volume:74 Page:125-130
ISSN:2255-890X
Container-title:Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.
language:en
Short-container-title:

Author:

Straume Zane¹²,Proskurina Anna²³,Strode Zanda²,Sekretarjovs Jurijs⁴,Skuja Vita¹²,Urķe Anete⁴,Lapiņa Anita¹,Derovs Aleksejs¹²

Affiliation:

1. Rīga East Clinical University Hospital , 2 Hipokrāta Str., Rīga , LV- 1038 , Latvia

2. Rīga Stradiņš University , 16 Dzirciema Str., Rīga , LV- 1007 , Latvia

3. Pauls Stradiņš Clinical University Hospital , 13 Pilsoņu Str., Rīga , LV- 1002 , Latvia

4. University of Latvia , 19 Raiņa Blvd., Rīga , Latvia

Abstract

Abstract Esophageal stenting is used in patients with malignant esophageal tumours to reduce dysphagia and inanition. The objective of this study was to analyse the main reasons for esophageal stenting in Rīga East Clinical University Hospital (RECUH) and their association with dysphagia and mortality. A cross-sectional study of all patients hospitalised in RECUH who received esophageal self-expanding metal stents (SEMS) from October 2013 to December 2015 was performed. A total of 29 patients, 24 (82.8%) male and 5 (17.2%) female, with mean age 63.7 ± 11.3 years, underwent the procedure. The most common indications for stenting were tumour-related stenosis (52.9%) and fistulae (17.6%). Mean time from establishing the diagnosis of esophageal cancer to stent placement was 338.6 days. Median survival after stenting was 4.8 months. A complex case of a patient requiring placement of three palliative stents illustrates the challenges of esophageal cancer care. Esophageal stent placement is an effective palliative method for treating tumour-related symptoms but carries risks of stent complications and fistula development over time. SEMS are being successfully used in cancer patient treatment in Latvia.

Publisher

Walter de Gruyter GmbH

Link

https://www.sciendo.com/pdf/10.2478/prolas-2020-0020

Reference20 articles.

1. Anonymous (2018). Kopsavilkums par onkoloģiskajiem pacientiem (Summary of Oncology Patients, 2001–2017). Slimību profilakses un kontroles centrs (Center for Disease Prevention and Control). https://www.spkc.gov.lv/lv/statistika-un-petijumi/statistika/veselibas-aprupes-statistika1 (accessed 28 February 2020) (in Latvian).

2. Bakheet, N., Park, J. H., Hu, H. T., Yoon, S. H., Kim, K. Y., Zhe, W., Jeon, J. Y., Song, H. Y. (2019). Fully covered self expandable esophageal metallic stents in patients with inoperable malignant disease who survived for more than 6 months after stent placement. Brit. J. Radiol., 92 (1100), 20190321.

3. Besharat, S., Jabbari, A., Semnani, S., Keshtkar, A., Marjani, J. (2008). Inoperable esophageal cancer and outcome of palliative care. World J. Gastroenterol., 14 (23), 3725–3728.

4. Bi, Y., Li, J., Yu, Z., Han, X., Wu, G. (2019). Modified type of double-covered self-expandable segmental metallic stents for palliation of esophageal fistula. J. Laparoendosc. Adv. Surg. Tech. A, 29 (7), 875–879.

5. Chauhan, S. S., Long, J. D. (2004). Management of tracheoesophageal fistulas in adults. Curr. Treatment Opt. Gastroenterol.,7 (1), 31–40.